Cost-Effectiveness of Biosimilars vs Leflunomide An economic evaluation of 25 099 rheumatoid arthritis patients found that treatment with biosimilar DMARDs were cost-effective compared with the conventional DMARD, leflunomide. https://t.co/lWJB1VL1CL https://t.co/lzra8suVqs